ReviewACS photonics2025
Unlocking the Translational Potential of Nanophotonic Biosensors: Perspectives on Application-Guided Design.
Review in ACS photonics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanocarbon as a Quantum Material for Biointerfaces and Magnetic Platforms in Theranostic Biomedicine in Oncology: A Critical Review.Biosensors · 2026Review
- Wafer-Scale All-Dielectric Quasi-BIC Metasurfaces: Bridging High-Throughput Deep-UV Lithography with Nanophotonic Applications.Nano letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Biochemical sensing platforms have become indispensable to critical decision-making across healthcare, security, and industrydelivering essential data that powers AI systems and shaping our modern lifestyles. This growing reliance on biosensors has elevated expectations, creating demand for portable, user-friendly, and cost-efficient platforms with ultrahigh sensitivity and specificity. Nanophotonic biosensors, which harness engineered subwavelength architectures to amplify light-matter interactions, offer transformative solutions through label-free, real-time, multiplexed detection capabilities. Despite compelling laboratory demonstrations, these technologies remain largely unrealized in real-world applications. This perspective examines the critical "valley of death" in technology transfer, where promising innovations stall before commercialization, while drawing strategic insights from surface plasmon resonance biosensors' successful commercialization journey. Highlighting technologies engineered for high-demand applications, we advocate an application-guided design approach to unlock nanophotonic sensors' translational potential. We share our perspectives on how this strategic framework offers a pathway through commercialization bottlenecks, accelerating the transformation from scientific achievement to societal impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.